111 related articles for article (PubMed ID: 481845)
1. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
Lokich JJ; Garnick MB; Legg M
Oncology; 1979; 36(5):236-41. PubMed ID: 481845
[TBL] [Abstract][Full Text] [Related]
2. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
[TBL] [Abstract][Full Text] [Related]
3. Re-inventing intratumoral immunotherapy for melanoma.
Triozzi PL; Tuthill RJ; Borden E
Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
[TBL] [Abstract][Full Text] [Related]
4. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
5. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
6. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
Coates AS; Peters M
Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in viral warts with intradermal
Podder I; Bhattacharya S; Mishra V; Sarkar TK; Chandra S; Sil A; Pal S; Kumar D; Saha A; Shome K; Bandyopadhyay D; Das NK
Indian J Dermatol Venereol Leprol; 2017; 83(3):411. PubMed ID: 27852999
[TBL] [Abstract][Full Text] [Related]
8. [Effect of intra-lesional injection of tuberculin-active protein on metastatic nodules of human malignant melanoma].
Saida T
Nihon Hifuka Gakkai Zasshi; 1982 Nov; 92(13):1399-414. PubMed ID: 6984865
[No Abstract] [Full Text] [Related]
9. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
de la Monte SM; Hutchins GM
Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
[TBL] [Abstract][Full Text] [Related]
10. Multiple cutaneous malignant melanomas with features of primary melanoma.
Unger SW; Wanebo HJ; Cooper PH
Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
12. Intralesional immunotherapy of melanoma with BCG.
Rosenberg SA; Rapp HJ
Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
[TBL] [Abstract][Full Text] [Related]
13. BCG immunotherapy in patients with malignant melanoma.
Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of active immunotherapy in patients with solid tumors.
Gerner RE; Moore GE
Cancer; 1976 Jul; 38(1):131-43. PubMed ID: 779950
[TBL] [Abstract][Full Text] [Related]
15. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
Felix EL; Jessup JM; Cohen MH
Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
[TBL] [Abstract][Full Text] [Related]
16. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma.
Bartal A; Cohen Y; Mekori T; Haasz R; Robinson E
Med Pediatr Oncol; 1979; 6(1):1-10. PubMed ID: 440203
[TBL] [Abstract][Full Text] [Related]
17. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER).
Kirkwood JM; Ariyan S; Nordlund JJ; Forget BM
Cancer; 1982 Oct; 50(7):1299-303. PubMed ID: 7104973
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of melanoma with intralesional BCG.
Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
[No Abstract] [Full Text] [Related]
19. Intralesional BCG application in malignant melanoma.
Sopková B; Kolár V
Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
[TBL] [Abstract][Full Text] [Related]
20. Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
Richman SP; Mavligit GM; Wolk R; Gutterman JU; Hersh EM
JAMA; 1975 Dec; 234(12):1233-5. PubMed ID: 1242748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
